Search Results - "PIRO, L. D"

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma by Piro, L. D., White, C. A., Grillo-López, A. J., Janakiraman, N., Saven, A., Beck, T. M., Varns, C., Shuey, S., Czuczman, M., Lynch, J. W., Kolit, J. E., Jain, V.

“…Background: Rituximab is a chimeric monoclonal antibody directed against the B-cell CD20 antigen which has been utilized for therapy of B-cell non-Hodgkin's…”
Get full text

Long-term follow-up of patients with hairy cell leukemia after cladribine treatment by SAVEN, A, BURIAN, C, KOZIOL, J. A, PIRO, L. D

“…Hairy cell leukemia is a chronic B-cell disorder that follows an indolent, but progressive course. Cladribine (2-chlorodeoxyadenosine) induces complete…”
Get full text

2-Chlorodeoxyadenosine treatment of low-grade lymphomas by Kay, A C, Saven, A, Carrera, C J, Carson, D A, Thurston, D, Beutler, E, Piro, L D

“…Because of the need to identify effective new agents in the treatment of non-Hodgkin's lymphoma and because of the high activity of the purine analog…”
Get more information

Relationship of Deoxycytidine Kinase and Cytoplasmic 5’-Nucleotidase to the Chemotherapeutic Efficacy of 2-Chlorodeoxyadenosine by Kawasaki, Hajime, Carrera, Carlos J., Piro, Lawrence D., Saven, Alan, Kipps, Thomas J., Carson, Dennis A.

“…The agent 2-chlorodeoxyadenosine (2-CdA) has chemotherapeutic activity in hairy cell leukemia (HCL) and in refractory chronic lymphocytic leukemia (CLL). The…”
Get full text

2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia by Saven, A, Lemon, R H, Kosty, M, Beutler, E, Piro, L D

“…2-chlorodeoxyadenosine (2-CdA; cladribine) is a purine analog with activity in patients with chronic lymphocytic leukemia (CLL) who fail to respond to…”
Get more information

Reduced charges and costs associated with outpatient autologous stem cell transplantation by MEISENBERG, B. R, FERRAN, K, HOLLENBACH, K, BREHM, T, JOLLON, J, PIRO, L. D

“…High-dose chemotherapy and stem cell rescue is increasingly being delivered in the outpatient setting. Such intensive outpatient management programs have…”
Get full text

Diagnostic Application of Two-Color Flow Cytometry in 161 Cases of Hairy Cell Leukemia by Robbins, Bruce A., Ellison, Douglas J., Spinosa, John C., Carey, Cristin A., Lukes, Robert J., Poppema, Sibrand, Saven, Alan, Piro, Lawrence D.

“…Recent immunophenotypic studies of hairy cell leukemia (HCL) have suggested specific patterns of immunoreactiv-ity that may aid in diagnosis. We studied…”
Get full text

Outpatient high-dose chemotherapy with autologous stem-cell rescue for hematologic and nonhematologic malignancies by Meisenberg, B R, Miller, W E, McMillan, R, Callaghan, M, Sloan, C, Brehm, T, Kosty, M P, Kroener, J, Longmire, R, Saven, A, Piro, L D

“…A prospective study to determine the feasibility of high-dose chemotherapy (HDC) and autologous stem-cell rescue (ASCR) in the outpatient setting. One hundred…”
Get more information

Lasting Remissions in Hairy-Cell Leukemia Induced by a Single Infusion of 2-Chlorodeoxyadenosine by Piro, Lawrence D, Carrera, Carlos J, Carson, Dennis A, Beutler, Ernest

“…2-Chlorodeoxyadenosine is a simple purine nucleoside that has previously been shown to be effective in the treatment of low-grade malignant disorders of…”
Get full text

2-Chlorodeoxyadenosine : a newer purine analog active in the treatment of indolent lymphoid malignancies by SAVEN, A, PIRO, L. D

“…To review the structure, mechanism of action, pharmacologic features, and clinical trial results of the newer purine analog, 2-chlorodeoxyadenosine (2-CdA)…”
Get full text

Treatment of Hairy Cell Leukemia by Saven, Alan, Piro, Lawrence D.

Get full text

Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia by ELLISON, D. J, SHARPE, R. W, ROBBINS, B. A, SPINOSA, J. C, LEOPARD, J. D, SAVEN, A, PIRO, L. D

“…Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA) induces complete remissions in 85% of patients. Complete remission has been defined as the…”
Get full text

Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo : a novel approach to immunosuppressive therapy by CARRERA, C. J, TERAI, C, LOTZ, M, CURD, J. G, PIRO, L. D, BEUTLER, E, CARSON, D. A

“…Lymphoid cells were thought to be uniquely susceptible to excess 2'-deoxyadenosine (dAdo), when exposed to inhibitors of adenosine deaminase (ADA). However, we…”
Get full text

Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy by Saven, A, Cheung, W K, Smith, I, Moyer, M, Johannsen, T, Rose, E, Gollard, R, Kosty, M, Miller, W E, Piro, L D

“…This study was designed to evaluate the absolute bioavailability (F value) of 2-chlorodeoxyadenosine (cladribine; 2-CdA) after multiple oral administrations,…”
Get more information

2-chlorodeoxyadenosine treatment of lymphoid malignancies by PIRO, L. D

Get full text

2-Chlorodeoxyadenosine: An Effective New Agent for the Treatment of Chronic Lymphocytic Leukemia by Piro, Lawrence D., Carrera, Carlos J., Beutler, Ernest, Carson, Dennis A.

“…2-Chlorodeoxyadenosine, a new lymphocyte-selective, anti-neoplastic drug was administered to 18 patients with advanced chronic lymphocytic leukemia of B-cell…”
Get full text

2-Chlorodeoxyadenosine dose escalation in nonhematologic malignancies by Saven, A, Kawasaki, H, Carrera, C J, Waltz, T, Copeland, B, Zyroff, J, Kosty, M, Carson, D A, Beutler, E, Piro, L D

“…We performed a dose-escalation study of 2-chlorodeoxyadenosine (2-CdA) in solid tumors to determine the maximum-tolerated dose (MTD) and define its toxicity…”
Get more information

2-Chlorodeoxyadenosine-induced complete remissions in Langerhans-cell histiocytosis by SAVEN, A, FOON, K. A, PIRO, L. D

Get full text

2-Chlorodeoxyadenosine: An Active Agent in the Treatment of Cutaneous T-Cell Lymphoma by Saven, Alan, Carrera, Carlos J., Carson, Dennis A., Beutler, Ernest, Piro, Lawrence D.

“…Cutaneous T-cell lymphomas are disfiguring malignant lymphoproliferative disorders for which standard therapy has been principally palliative…”
Get full text

Cladribine in the treatment of low-grade non-Hodgkin's lymphoma by Piro, L D

Get more information